Management of h

hypertension
ypertension

NICE Pathways bring together everything NICE says on a topic in an interactive

flowchart. NICE Pathways are interactive and designed to be used online.

They are updated regularly as new NICE guidance is published. To view the latest
version of this NICE Pathway see:

http://pathways.nice.org.uk/pathways/hypertension
NICE Pathway last updated: 27 March 2018

This document contains a single flowchart and uses numbering to link the boxes to the
associated recommendations.

Hypertension Page 1 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
 Management of h
hypertension
ypertension NICE Pathways

Hypertension Page 2 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
 Management of h
hypertension
ypertension NICE Pathways

1 Adult with hypertension

No additional information

2 Lifestyle interventions

For guidance on the prevention of obesity and cardiovascular disease, see what NICE says on
obesity and cardiovascular disease prevention.

Lifestyle advice should be offered initially and then periodically to people undergoing
assessment or treatment for hypertension.

Ascertain people's diet and exercise patterns because a healthy diet and regular exercise can
reduce blood pressure. Offer appropriate guidance and written or audiovisual materials to
promote lifestyle changes.

Relaxation therapies can reduce blood pressure and people may wish to pursue these as part
of their treatment. However, routine provision by primary care teams is not currently
recommended.

Ascertain people's alcohol consumption and encourage a reduced intake if they drink
excessively, because this can reduce blood pressure and has broader health benefits.

Discourage excessive consumption of coffee and other caffeine-rich products.

Encourage people to keep their dietary sodium intake low, either by reducing or substituting
sodium salt, as this can reduce blood pressure.

Do not offer calcium, magnesium or potassium supplements as a method for reducing blood
pressure.

Offer advice and help to smokers to stop smoking.

A common aspect of studies for motivating lifestyle change is the use of group working. Inform
people about local initiatives by, for example, healthcare teams or patient organisations that
provide support and promote healthy lifestyle change.

Hypertension Page 3 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
 Management of h
hypertension
ypertension NICE Pathways

See what NICE says on alcohol-use disorders, diet, physical activity, and stop smoking
interventions and services.

3 Criteria for starting antihypertensive drug treatment

Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension
who have one or more of the following:

target organ damage

established cardiovascular disease
renal disease
diabetes
10-year cardiovascular risk equivalent to 20% or greater.

Offer antihypertensive drug treatment to people of any age with stage 2 hypertension.

Quality standards

The following quality statement is relevant to this part of the interactive flowchart.

3. Statin therapy

4 Choosing antihypertensive drug treatment

Where possible, recommend treatment with drugs taken only once a day.

Prescribe non-proprietary drugs where these are appropriate and minimise cost.

Offer people with isolated systolic hypertension (systolic blood pressure 160 mmHg or more) the
same treatment as people with both raised systolic and diastolic blood pressure.

Do not combine an ACE inhibitor with an ARB to treat hypertension1.

For information about antihypertensive drug treatment, see treatment steps for hypertension.

People aged over 80 years

Offer people aged 80 years and over the same antihypertensive drug treatment as people aged
55–80 years, taking into account any comorbidities.

Hypertension Page 4 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
1
In 2007 the MHRA issued a drug safety update on ACE inhibitors and angiotensin II receptor antagonists: not for
use in pregnancy that states 'Use in women who are planning pregnancy should be avoided unless absolutely
necessary, in which case the potential risks and benefits should be discussed'. There is also a 2009 MHRA safety
update for ACE inhibitors and angiotensin II receptor antagonists: use during breast feeding and related
clarification: ACE inhibitors and angiotensin II receptor antagonists.

Hypertension Page 5 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
 Management of h
hypertension
ypertension NICE Pathways

Women of child-bearing potential

Offer antihypertensive drug treatment to women of child-bearing potential in line with NICE's
recommendations on chronic hypertension and on breastfeeding for hypertension in pregnancy.

5 Blood pressure targets

Aim for a target clinic blood pressure below 140/90 mmHg in people aged under 80 years with
treated hypertension.

Aim for a target clinic blood pressure below 150/90 mmHg in people aged 80 years and over,
with treated hypertension.

When using ABPM or HBPM to monitor response to treatment (for example, in people identified
as having a white coat effect and people who choose to monitor their blood pressure at home),
aim for a target average blood pressure during the person's usual waking hours of:

below 135/85 mmHg for people aged under 80 years

below 145/85 mmHg for people aged 80 years and over.

For guidance on blood pressure control and antihypertensive treatment in people with chronic
kidney disease, see blood pressure control and antihypertensive treatment in NICE's
recommendations on chronic kidney disease.

For guidance on managing blood pressure in people with type 1 diabetes, see blood pressure
management in NICE's recommendations on type 1 diabetes in adults.

For guidance on targets for blood pressure for people with type 2 diabetes, see blood pressure
measurement and targets in NICE's recommendations on type 2 diabetes in adults.

Quality standards

The following quality statement is relevant to this part of the interactive flowchart.

4. Blood pressure targets

Hypertension Page 6 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
 Management of h
hypertension
ypertension NICE Pathways

6 Patient education and adherence to treatment

Provide appropriate guidance and materials about the benefits of drugs and the unwanted side
effects sometimes experienced in order to help people make informed choices.

People vary in their attitudes to their hypertension and their experience of treatment. It may be
helpful to provide details of patient organisations that provide useful forums to share views and
information.

Interventions to support adherence to treatment

Because evidence supporting interventions to increase adherence is inconclusive, only use

interventions to overcome practical problems associated with non-adherence if a specific need
is identified. Target the intervention to the need. Interventions might include:

suggesting that patients record their medicine-taking

encouraging patients to monitor their condition
simplifying the dosing regimen
using alternative packaging for the medicine
using a multi-compartment medicines system.

7 Treatment steps for hypertension

See Hypertension / Treatment steps for hypertension

8 See what NICE says on medicines optimisation

See Medicines optimisation

Hypertension Page 7 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
Management of h
hypertension
ypertension NICE Pathways

Glossary

ACE inhibitor

angiotensin-converting enzyme inhibitor

ARB

angiotensin II receptor blocker

CCB

calcium-channel blocker

ABPM

ambulatory blood pressure monitoring

eGFR

estimated glomerular filtration rate

HBPM

home blood pressure monitoring

Severe hypertension

clinic systolic blood pressure is 180 mmHg or higher or clinic diastolic blood pressure is 110
mmHg or higher

Stage 1 hypertension

clinic blood pressure 140/90 mmHg or higher and subsequent ambulatory blood pressure
monitoring daytime average or home blood pressure monitoring average blood pressure 135/85
mmHg or higher

Hypertension Page 8 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
Management of h
hypertension
ypertension NICE Pathways

Stage 2 hypertension

clinic blood pressure 160/100 mmHg or higher and subsequent ambulatory blood pressure
monitoring daytime average or home blood pressure monitoring average blood pressure 150/95
mmHg or higher

White-coat effect

a discrepancy of more than 20/10 mmHg between clinic and average daytime ambulatory blood
pressure monitoring or average home blood pressure monitoring measurements at the time of
diagnosis

Sources

Hypertension in adults: diagnosis and management (2011 updated 2016) NICE guideline
CG127

Medicines adherence: involving patients in decisions about prescribed medicines and

supporting adherence (2009) NICE guideline CG76

Your responsibility

Guidelines

The recommendations in this guideline represent the view of NICE, arrived at after careful
consideration of the evidence available. When exercising their judgement, professionals and
practitioners are expected to take this guideline fully into account, alongside the individual
needs, preferences and values of their patients or the people using their service. It is not
mandatory to apply the recommendations, and the guideline does not override the responsibility
to make decisions appropriate to the circumstances of the individual, in consultation with them
and their families and carers or guardian.

Local commissioners and providers of healthcare have a responsibility to enable the guideline
to be applied when individual professionals and people using services wish to use it. They
should do so in the context of local and national priorities for funding and developing services,
and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to

Hypertension Page 9 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
Management of h
hypertension
ypertension NICE Pathways

advance equality of opportunity and to reduce health inequalities. Nothing in this guideline
should be interpreted in a way that would be inconsistent with complying with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable

health and care system and should assess and reduce the environmental impact of
implementing NICE recommendations wherever possible.

Technology appraisals

The recommendations in this interactive flowchart represent the view of NICE, arrived at after
careful consideration of the evidence available. When exercising their judgement, health
professionals are expected to take these recommendations fully into account, alongside the
individual needs, preferences and values of their patients. The application of the
recommendations in this interactive flowchart is at the discretion of health professionals and
their individual patients and do not override the responsibility of healthcare professionals to
make decisions appropriate to the circumstances of the individual patient, in consultation with
the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable
the recommendations to be applied when individual health professionals and their patients wish
to use it, in accordance with the NHS Constitution. They should do so in light of their duties to
have due regard to the need to eliminate unlawful discrimination, to advance equality of
opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable

health and care system and should assess and reduce the environmental impact of
implementing NICE recommendations wherever possible.

Medical technologies guidance, diagnostics guidance and interventional procedures

guidance

The recommendations in this interactive flowchart represent the view of NICE, arrived at after
careful consideration of the evidence available. When exercising their judgement, healthcare
professionals are expected to take these recommendations fully into account. However, the
interactive flowchart does not override the individual responsibility of healthcare professionals to

Hypertension Page 10 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.
Management of h
hypertension
ypertension NICE Pathways

make decisions appropriate to the circumstances of the individual patient, in consultation with
the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the recommendations, in

their local context, in light of their duties to have due regard to the need to eliminate unlawful
discrimination, advance equality of opportunity, and foster good relations. Nothing in this
interactive flowchart should be interpreted in a way that would be inconsistent with compliance
with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable

health and care system and should assess and reduce the environmental impact of
implementing NICE recommendations wherever possible.

Hypertension Page 11 of 11
© NICE 2018. All rights reserved. Subject to Notice of rights.